ECSP11010925A - Partículas inhalables que comprenden tiotropio - Google Patents

Partículas inhalables que comprenden tiotropio

Info

Publication number
ECSP11010925A
ECSP11010925A EC2011010925A ECSP11010925A ECSP11010925A EC SP11010925 A ECSP11010925 A EC SP11010925A EC 2011010925 A EC2011010925 A EC 2011010925A EC SP11010925 A ECSP11010925 A EC SP11010925A EC SP11010925 A ECSP11010925 A EC SP11010925A
Authority
EC
Ecuador
Prior art keywords
inhalable particles
tiotropio
tiotropium
stabilized
refers
Prior art date
Application number
EC2011010925A
Other languages
English (en)
Inventor
Karim Amighi
Guerra Antonio Sereno
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40348057&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of ECSP11010925A publication Critical patent/ECSP11010925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrolytic Production Of Metals (AREA)

Abstract

La presente invención se refiere a partículas inhalables que comprenden una forma amorfa de tiotropio estabilizada con un agente estabilizante. También se refiere a las partículas inhalables que comprenden una forma amorfa de tiotropio estabilizada con un agente estabilizante mezclado con uno o más excipientes gruesos de un tamaño medio de partícula de 15 a 250 µm. También se refiere a una composición farmacéutica que comprende las partículas inhalables de la invención, a un procedimiento para su preparación y a su uso para la preparación de un medicamento para el tratamiento del asma o de la enfermedad pulmonar obstructiva crónica (EPOC).
EC2011010925A 2008-10-02 2011-03-29 Partículas inhalables que comprenden tiotropio ECSP11010925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08382040A EP2172190A1 (en) 2008-10-02 2008-10-02 Inhalable particles comprising tiotropium
US10411308P 2008-10-09 2008-10-09

Publications (1)

Publication Number Publication Date
ECSP11010925A true ECSP11010925A (es) 2011-07-29

Family

ID=40348057

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010925A ECSP11010925A (es) 2008-10-02 2011-03-29 Partículas inhalables que comprenden tiotropio

Country Status (38)

Country Link
US (1) US20110311618A1 (es)
EP (2) EP2172190A1 (es)
JP (1) JP5622730B2 (es)
KR (1) KR101639089B1 (es)
CN (1) CN102170861B (es)
AR (1) AR073528A1 (es)
AU (1) AU2009299801B2 (es)
BR (1) BRPI0920706B8 (es)
CA (1) CA2737399C (es)
CL (1) CL2011000696A1 (es)
CO (1) CO6361899A2 (es)
CR (1) CR20110227A (es)
CY (1) CY1121090T1 (es)
DK (1) DK2349204T3 (es)
DO (1) DOP2011000091A (es)
EC (1) ECSP11010925A (es)
ES (1) ES2675857T3 (es)
HN (1) HN2011000864A (es)
HR (1) HRP20181009T1 (es)
HU (1) HUE038208T2 (es)
LT (1) LT2349204T (es)
MA (1) MA34560B1 (es)
MX (1) MX2011003491A (es)
MY (1) MY159172A (es)
NI (1) NI201100066A (es)
NZ (1) NZ591923A (es)
PE (2) PE20142435A1 (es)
PL (1) PL2349204T3 (es)
PT (1) PT2349204T (es)
RU (2) RU2685236C2 (es)
SI (1) SI2349204T1 (es)
SV (1) SV2011003852A (es)
TR (1) TR201808269T4 (es)
TW (1) TWI433675B (es)
UA (1) UA100777C2 (es)
UY (1) UY32160A (es)
WO (1) WO2010037845A1 (es)
ZA (1) ZA201101735B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011179A (es) * 2010-03-31 2013-03-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica en polvo para inhalacion.
US9259376B2 (en) 2010-06-03 2016-02-16 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Process for dry powder formulations
WO2011154014A1 (en) * 2010-06-11 2011-12-15 Gea Process Engineering A/S Controlled humidity drying
EA201300255A1 (ru) 2010-08-23 2013-06-28 Такеда Гмбх Увлажненные частицы, содержащие терапевтически активное вещество
EP2804591A2 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Preparation of dry powder formulations comprising tiotropium
DE102013012914A1 (de) 2012-08-03 2014-02-20 Gheorghe George Olaru Hot runner injection molding apparatus with additional controller
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
EP4108230A1 (en) * 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation
GR1010358B (el) * 2021-09-14 2022-12-16 Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, Σταθερο φαρμακευτικο σκευασμα που περιεχει βρωμιουχο τιοτροπιο, για χορηγηση απο το αναπνευστικο
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
CA2395653C (en) 2000-10-12 2006-05-09 Boehringer Ingelheim Pharma Kg New inhalable powder containing tiotropium
BRPI0116793B8 (pt) * 2000-12-14 2021-05-25 Johnson & Johnson produtos de hormônio de esteróide e métodos para prepará-los
US6485279B2 (en) * 2000-12-26 2002-11-26 Carrier Corporation Thrust load reliever
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
JP2005520843A (ja) * 2002-03-20 2005-07-14 アドバンスト インハレーション リサーチ，インコーポレイテッド 呼吸用持続性治療製剤
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
BRPI0608427A2 (pt) * 2005-12-19 2009-12-29 Sicor Inc novas formas de brometo de tiotrópio e processos para seu preparo
AU2007208998A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations

Also Published As

Publication number Publication date
US20110311618A1 (en) 2011-12-22
PE20142435A1 (es) 2015-01-11
JP5622730B2 (ja) 2014-11-12
RU2011117256A (ru) 2012-11-10
AU2009299801A1 (en) 2010-04-08
BRPI0920706A2 (pt) 2015-12-29
HN2011000864A (es) 2015-02-09
AR073528A1 (es) 2010-11-10
BRPI0920706B8 (pt) 2021-05-25
NI201100066A (es) 2012-01-05
ZA201101735B (en) 2012-05-30
CN102170861A (zh) 2011-08-31
MX2011003491A (es) 2011-06-16
CL2011000696A1 (es) 2011-07-29
WO2010037845A1 (en) 2010-04-08
KR101639089B1 (ko) 2016-07-12
TW201018468A (en) 2010-05-16
DOP2011000091A (es) 2011-04-30
PL2349204T3 (pl) 2018-09-28
LT2349204T (lt) 2018-10-10
HUE038208T2 (hu) 2018-10-29
PT2349204T (pt) 2018-07-06
CY1121090T1 (el) 2019-12-11
HRP20181009T1 (hr) 2018-08-24
SI2349204T1 (en) 2018-08-31
EP2349204A1 (en) 2011-08-03
TR201808269T4 (tr) 2018-07-23
RU2014150986A (ru) 2015-06-10
JP2012504580A (ja) 2012-02-23
RU2685236C2 (ru) 2019-04-17
UY32160A (es) 2010-04-30
RU2014150986A3 (es) 2018-07-02
AU2009299801B2 (en) 2014-02-27
ES2675857T3 (es) 2018-07-13
BRPI0920706B1 (pt) 2021-02-02
CO6361899A2 (es) 2012-01-20
TWI433675B (zh) 2014-04-11
DK2349204T3 (en) 2018-07-16
MA34560B1 (fr) 2013-10-02
KR20110081265A (ko) 2011-07-13
EP2349204B1 (en) 2018-04-11
PE20110850A1 (es) 2011-11-25
EP2172190A1 (en) 2010-04-07
SV2011003852A (es) 2011-04-12
CA2737399C (en) 2017-02-21
CN102170861B (zh) 2014-05-14
CR20110227A (es) 2011-06-24
MY159172A (en) 2016-12-30
UA100777C2 (ru) 2013-01-25
NZ591923A (en) 2012-02-24
CA2737399A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CO6361899A2 (es) Pariculas inhalables que comprenden tiotropio
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
UY31686A1 (es) Nueva dosificacion y formulacion
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
UY31687A1 (es) Nueva dosificacion y formulacion
CL2014001966A1 (es) Formulación seca en polvo que comprende a)una fracción de partículas finas, b)una fraccion de particulas gruesas y c) dihidrato del fumarato de formoterol en combinacion con dipropionato de beclometasona, como ingredientes activos; inhalador de polvo seco; uso en la prevencion y/o el tratamiento de asma o enfermedad pulmonar obstructiva crónica.
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
BRPI1008227A8 (pt) composição de glicocorticoide inalável para uso na terapia de um paciente que sofre de asma severa e sem controle.
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
CL2011001977A1 (es) Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades.
WO2013138628A3 (en) Injectable ibuprofen formulation
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
TN2012000431A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
EA201201392A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
BRPI0911464A2 (pt) composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de doenças do trato urinário inferior em um mamífero, e, uso do composto ou uma pró-droga do mesmo
UY30934A1 (es) Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones.
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
EA201201394A1 (ru) Ингалятор для доставки лекарственного средства в виде сухого порошка
TN2011000121A1 (en) Inhalable particles comprising tiotropium
WO2014062143A3 (en) Combinations of glycopyrrolate and an anticholinergic agent